Subjects aged ≥55 years with probable Dementia with Lewy Bodies DLB by consensus criteria (McKeith et al research hub

A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)

This study is looking at a new medicine called neflamapimod for people with a type of memory problem called Dementia with Lewy Bodies (DLB). It aims to see if this medicine can help improve memory and thinking over 16 weeks.